Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Zakhar Nudelman"'
Autor:
Eran Lavy, David Kirmayer, Zakhar Nudelman, Liya Orenshtein-Vilensky, Timothy G Rowan, Julia Shenderovich-Gefter, Michael Friedman
Publikováno v:
Veterinary and Animal Science, Vol 15, Iss , Pp 100235- (2022)
The controlled release of drugs is an appealing area of research as it provides numerous benefits in veterinary and human medicine. In this paper we attempt to analyze certain aspects related to topical drug delivery systems, their successes and fail
Externí odkaz:
https://doaj.org/article/91d388dbf5d1484ebef17e11ee43f06e
Autor:
Rakefet, Czerninski, Ori, Finfter, Zakhar, Nudelman, Yuval, Tal, David, Kirmayer, Michael, Friedman
Publikováno v:
Quintessence international (Berlin, Germany : 1985).
Maintaining appropriate salivary levels of an active ingredient is challenging. Intraoral trays can be used to deliver medications for localized treatment. Based on previous successful daytime studies with a slow-release sirolimus varnish, we aim to
Autor:
Zakhar Nudelman, Michael Friedman, David Kirmayer, Rakefet Czerninski, Ori Finfter, Yuval Tal
Publikováno v:
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 131:e115
Objectives Intraoral trays can be used to deliver treatment materials and medications for dental or mucosal conditions. Maintaining appropriate salivary levels of the active ingredient is challenging when using local application. We have previously a
Autor:
Maamoun Basheer, Mordechai Findler, David Kirmayer, J. Silvio Gutkind, Zakhar Nudelman, Rakefet Czerninski, Alina Nemirovski, Dinorah Barasch, Anna Pikovsky, Michael Friedman
Publikováno v:
Cancer Chemotherapy and Pharmacology. 75:969-974
Sirolimus (rapamycin) is a mammalian target of rapamycin pathway blocker. The efficacy of sirolimus is currently studied for its antiproliferative properties in various malignancies and particularly in squamous cell carcinoma and other oral disorders
Autor:
Michael Friedman, JS Gutkind, Mordechai Findler, Alina Nemirovski, Zakhar Nudelman, Dinorah Barasch, Rakefet Czerninski, Anna Pikovsky
Publikováno v:
Oral diseases. 20(8)
Objectives Sirolimus (rapamycin) is a mammalian target of rapamycin (mTOR) inhibitor with antiproliferative activity. Its systemic administration is currently evaluated for the management of squamous cell carcinoma and various oral disorders. Topical
Autor:
Zakhar, Nudelman, Naama, Keshet, Michal Dranitzki, Elhalal, Michael, Friedman, Rakefet, Czerninski
Publikováno v:
Anticancer research. 33(2)
Sirolimus is a potent blocker of mammalian target of Rapamycin (MTOR), with anti proliferative activity. Its potential for the management of oral cancer has been suggested. Our aim was to establish an analytical method for determining sirolimus level
Autor:
Rakefet Czerninski, Michal Dranitzki Elhalal, Zakhar Nudelman, Michael Friedman, Naama Keshet
Publikováno v:
Oral Oncology. 49:S138
Purpose Sirolimus, currently used as an immunosuppressant, is a potent mammalian target of rapamycin blocker with antiproliferative activity. Its potential for the management of oral pathologies and cancer and has been suggested. Topical application